Some rich people are betting a lot of money that a company called Bristol-Myers Squibb will do well in the future. They are buying special contracts called options that give them the right to buy or sell the company's stock at a certain price. This can make them a lot of money if the stock price goes up or down. Other people who follow the stock market think the company's stock might go up or down too, but they don't know what will happen for sure. The company makes medicine for people who are sick, and they are trying to make better medicines that help the body fight cancer. Read from source...

- The article title is misleading and clickbait: "Smart Money Is Betting Big In BMY Options" implies that some knowledgeable or wealthy investors are making large bets on BMY options, but it does not provide any evidence or reasoning for this claim.
- The article uses vague and ambiguous terms like "big players", "significant move", "something big is about to happen" without explaining what these terms mean or how they are measured.
- The article relies heavily on Benzinga's options scanner data without providing any context or analysis of the market conditions, the historical trends, or the underlying factors that could influence the options prices.
- The article does not mention any of the options contracts that were traded, such as the strike price, the expiration date, the volume, the open interest, or the bid-ask spread, which are essential details for understanding the options market dynamics.
- The article does not provide any link or reference to the original sources of the options data, making it difficult to verify the accuracy and reliability of the information.
- The article does not discuss the company's fundamentals, its competitive position, its business model, its growth prospects, or its valuation, which are important factors for evaluating the stock and the options.
- The article ends with a promotional message for Benzinga Pro, which seems unrelated and irrelevant to the main topic of the article.

Overall, the article is poorly written, lacks credibility, and offers little value to the readers. It seems like a thinly veiled attempt to promote Benzinga's services and to generate traffic through sensational headlines. I would give this article a D grade.

Neutral
Article's Content: The article discusses the large options activity for Bristol-Myers Squibb, a pharmaceutical company, with a mix of bullish and bearish bets. The author suggests that this activity may indicate something big is about to happen for the company. The article also provides some analysis of the company's recent performance and expert opinions on the stock.